Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimers 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, March 9, 2022
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Clinical Trials, Savara, Degenerative disease, Granulocyte-macrophage colony-stimulating factor, Inc., Pulmonology, GM-CSF, Twitter, Conference, APAP, LinkedIn, Pharmaceutical industry
Geotags: 
UNITED STATES, NORTH AMERICA, TEXAS
⚠ generated by AI ↴
Organisation: 
SAVARA
Stock Symbol: 
NASDAQ:SVRA
Summary
Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimers 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET.
  • A live webcast of the presentation will be available on Savaras website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
  • Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
  • Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Copyright: 
Copyright Business Wire 2022